Medicine-Induced Acute Kidney Injury Findings from Spontaneous Reporting Systems, Sequence Symmetry Analysis and a Case-Control Study with a Focus on Medicines Used in Primary Care

Drug Saf. 2022 Nov;45(11):1413-1421. doi: 10.1007/s40264-022-01238-4. Epub 2022 Sep 21.

Abstract

Introduction: Primary care provides an opportunity to prevent community acquired, medicine or drug-induced acute kidney injury. One of the barriers to proactive prevention of medicine-induced kidney injury in primary care is the lack of a list of nephrotoxic medicines that are most problematic in primary care, particularly one that provides a comparison of risks across medicines.

Objective: The aim of this study was to consolidate evidence on the risks associated with medicines and acute kidney injury, with a focus on medicines used in primary care.

Method: We searched the MEDLINE and EMBASE databases to identify published studies of all medicines associated with acute kidney injury identified from spontaneous report data. For each medicine positively associated with acute kidney injury, as identified from spontaneous reports, we implemented a sequence symmetry analysis (SSA) and a case-control design to determine the association between the medicine and hospital admission with a primary diagnosis of acute kidney injury (representing community-acquired acute kidney injury). Administrative claims data held by the Australian Government Department of Veterans' Affairs for the study period 2005-2019 were used.

Results: We identified 89 medicines suspected of causing acute kidney injury based on spontaneous report data and a reporting odds ratio above 2, from Japan, France and the US. Spironolactone had risk estimates of 3 or more based on spontaneous reports, SSA and case-control methods, while furosemide and trimethoprim with sulfamethoxazole had risk estimates of 1.5 or more. Positive association with SSA and spontaneous reports, but not case control, showed zoledronic acid had risk estimates above 2, while candesartan telmisartan, simvastatin, naproxen and ibuprofen all had risk estimates in SSA between 1.5 and 2. Positive associations with case-control and spontaneous reports, but not SSA, were found for amphotericin B, omeprazole, metformin, amlodipine, ramipril, olmesartan, ciprofloxacin, valaciclovir, mycophenolate and diclofenac. All with the exception of metformin and omeprazole had risk estimates above 2.

Conclusion: This research highlights a number of medicines that may contribute to acute injury; however, we had an insufficient sample to confirm associations of some medicines. Spironolactone, furosemide, and trimethoprim with sulfamethoxazole are medicines that, in particular, need to be used carefully and monitored closely in patients in the community at risk of acute kidney injury.

MeSH terms

  • Acute Kidney Injury* / chemically induced
  • Acute Kidney Injury* / epidemiology
  • Adverse Drug Reaction Reporting Systems
  • Amlodipine / adverse effects
  • Amphotericin B / adverse effects
  • Australia
  • Case-Control Studies
  • Ciprofloxacin / adverse effects
  • Diclofenac / adverse effects
  • Furosemide / adverse effects
  • Humans
  • Ibuprofen / adverse effects
  • Metformin* / adverse effects
  • Naproxen / adverse effects
  • Omeprazole / adverse effects
  • Primary Health Care
  • Ramipril / adverse effects
  • Simvastatin / adverse effects
  • Spironolactone / adverse effects
  • Sulfamethoxazole / adverse effects
  • Telmisartan / adverse effects
  • Trimethoprim / adverse effects
  • Valacyclovir / adverse effects
  • Zoledronic Acid / adverse effects

Substances

  • Diclofenac
  • Amlodipine
  • Spironolactone
  • Naproxen
  • Ciprofloxacin
  • Zoledronic Acid
  • Furosemide
  • Amphotericin B
  • Metformin
  • Simvastatin
  • Trimethoprim
  • Sulfamethoxazole
  • Omeprazole
  • Ramipril
  • Valacyclovir
  • Telmisartan
  • Ibuprofen